MEDITOR LAUNCHES MTR 104 TRIAL

Meditor Pharmaceuticals has begun a Phase II clinical trial for its proprietary lead development compound MTR 104, a low molecular weight isothiourea derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension.

The trial of MTR 104 is for intradialytic hypotension (IDH). The double blind clinical study will involve chronic renal failure patients who experience IDH.